Skip to content

Simply CMT

Accelerating Research. Empowering Patients. Making It Make Sense.

Featured News


All News

Search Simply CMT by Category

Search Simply CMT by Category
  • New CMTA-Funded Research to Test if an Existing Drug Can Help People with CMT1B and CMT1E 
    CMT1B and CMT1E Research: Can Existing Drugs Treat Nerve Damage?

    CMT1B and CMT1E can take away strength, feeling, and balance from damage to the nerve…

  • New Clinical Trial Recommendations for CMT Help Speed Therapies to Patients
    Shaping CMT Clinical Trials

    CMTA is leading efforts to improve CMT clinical trials through new recommendations that help create…

  • The Community We Needed, The Community We Built: Dear Younger Me 
    The Community We Needed, The Community We Built: Dear Younger Me

    Footprint Fellowship mentors reflect on growing up with CMT and share the advice and hope…

  • CMTA-STAR Alliance Partner Vanda Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for CMT2S Therapy Candidate 
    CMTA-STAR Alliance Partner Vanda Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for CMT2S Therapy Candidate

    CMTA Strategy to Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals has announced that the U.S. Food…

  • More Miles, Less Fatigue: Walking Poles and CMT 
    Walking Poles and CMT

    Travel means more time on your feet, navigating new terrain like cobblestones, stairs, gravel, or uneven pavement.…

  • Is Spinal Fluid the Way to Gene Therapy in CMT? What a Decade of Research Reveals 
    Is Spinal Fluid the Way to Gene Therapy in CMT?

    Most kinds of CMT come from a problem in a single gene. Repairing that faulty…

  • CMTA Leading the Way in CMT1A
    CMTA Leading the Way in CMT1A

    CMTA is leading a coordinated CMT1A research strategy that connects disease models, drug development, biomarkers,…

  • CMTA research takes the stage at PNS
    CMTA research takes the stage at PNS

    PNS 2026 showcased CMTA’s role in advancing CMT research across the translational pipeline, from biomarkers…

  • What Filspari Means for People with CMTDIE 
    What Filspari Means for People with CMTDIE

    FDA approval of Filspari creates a new treatment option for FSGS that may benefit some…

  • CMTA Expands Preclinical Toolbox with New CMT1A Assay
    New CMT1A Assay Now Available

    CMTA expands its Preclinical Toolbox with a new CMT1A assay, providing researchers with a human-relevant…

  • What 465 People with CMT1A Want Researchers to Know
    What 465 People with CMT1A Want Researchers to Know

    Results from a patient survey conducted by CMTA, CMT France, and Nervosave Therapeutics highlight what…

  • The Biggest Battle Wasn’t CMT
    The Biggest Battle Wasn’t CMT

    Arienna Hauser-Brown reflects on growing up with Charcot-Marie-Tooth disease (CMT) and how learning to overcome…